Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 1996

View Archived Issues

New antibacterial agents under study at Bayer

Reversible cysteine protease inhibitors reported by Arris

PDE IV inhibitors reported by E. Merck

Natural antiplatelet agent discovered at Kitasato Institute

Natural farnesyltransferase inhibitors from Kitasato Institute

NEP inhibitors claimed by Santen

Company profile: MediGene

Novel anticonvulsant described by SmithKline Beecham

Potent, orally active antiplatelet agent discovered by Merck & Co.

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Asian distribution agreement signed for Advanced Magnetics' liver contrast agent

rhBMP-2 cleared for limited clinical trial for spine fusion

Cortecs, Inflazyme collaborate on tests for TB

Disappointing results reported for genital herpes vaccine

Zeneca submits antimigraine Rx for approval

Antimicrobial ranalexin peptides available for licensing

Purified or recombinant TAP 29 with anti-HIV activity available for licensing

Exclusive worldwide rights offered for human full-length TRK-B

Diagnostic kits for beta-thalassemia available for licensing

Cancer diagnostic based on p53 offered for licensing

Exclusive worldwide rights offered for peptide-cleaving endopeptidase

Novel vaccine delivery system available for licensing

Licenses available for lung function monitor

Intracardiac illuminator offered for licensing

Canadian scientists identify new target for respiratory drugs

New 5-FU formulation reduces toxicity in mice

Another European market introduction for Epivir

New market introduction for antiestrogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...